Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B

World Journal of Gastroenterology

Volumn 21, Issue 18, 2015, Pages 5524-5531

  Pan, Calvin Q ^a   Chan, Sing ^b   Trinh, Huy ^c   Yao, Alan ^d   Bae, Ho ^e   Lou, Lillian ^f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Flushing   (United States)

^c San Jose Gastroenterology   (United States)

^d Flushing   (United States)

^e ST VINCENT MEDICAL CENTER   (United States)

^f Nexus Development   (United States)

Author keywords

Asian patients; Chronic hepatitis B; Fibrosis; High viral load; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; TENOFOVIR; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; BODY MASS; CHRONIC HEPATITIS B; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HEPATITIS B VIRUS GENOTYPE E; HEPATITIS B VIRUS GENOTYPE F; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; VIRUS LOAD; ANTIVIRAL RESISTANCE; ASIAN AMERICAN; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; EPIDEMIOLOGY; ETHNOLOGY; FACTUAL DATABASE; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASIAN AMERICANS; BIOMARKERS; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; TENOFOVIR; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84929151923     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i18.5524     Document Type: Article

References (18)

1. Gilead Sciences. VIREAD® prescribing information. Accessed 2 June 2014. Available from: URL: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/viread/viread-pi.pdf
2. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]
4. Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011; 56: 3143-3162 [PMID: 21935699 DOI: 10.1007/s10620-011-1841-5]
5. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455 [PMID: 19052126 DOI: 10.1056/NEJMoa0802878]
6. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]
7. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207-1217 [PMID: 20600025 DOI: 10.1053/j.gastro.2010.06.053]
8. Fung S, Kwan P, Fabri MJ, Horban A, Pelemis M, Husa P, Hann HW, Flaherty JF, Massetto B, Dinh P, Corsa AC, Kitrinos KM, Mchutchinson JG, Gane EJ. Efficacy and safety of tenofovir DF in chronic hepatitis B virus infected patients with documented lamivudine resistance. Hepatology 2012; 56 (Suppl): S14
9. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146: 980-988 [PMID: 24368224 DOI: 10.1053/j.gastro.2013.12.028]
10. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty JF, McHutchison JG, Manns M. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014; 60: 715-722 [PMID: 24295873 DOI: 10.1016/j.jhep.2013.11.024]
11. Pan CQ, Hu KQ, Tsai N. Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. Antivir Ther 2013; 18: 841-852 [PMID: 23178555 DOI: 10.3851/IMP2481]
12. Pan CQ, Trinh H, Yao A, Bae H, Lou L, Chan S. Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. PLoS One 2014; 9: e89789 [PMID: 24594870 DOI: 10.1371/journal.pone.0089789]
13. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a noninvasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 22-39 [PMID: 18973844 DOI: 10.1016/S0399-8320(08)73991-5]
14. Kim BK, Kim SU, Kim HS, Park JY, Ahn SH, Chon CY, Cho IR, Joh DH, Park YN, Han KH, Kim do Y. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One 2012; 7: e35825 [PMID: 22536445 DOI: 10.1371/journal.pone.0035825]
15. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763-773 [PMID: 21374657 DOI: 10.1002/hep.24078]
16. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013; 58: 505-513 [PMID: 23364953 DOI: 10.1002/hep.26277]
17. Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington MK, Barnes CN, Bornstein JD, Flaherty JF, Heathcote EJ. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54: 1038A
18. Pan CQ, Zeng Z, Bae H, Trinh HN, Ma x, Mi LJ, LeducTS, Chan S, Hu KQ. Three-year outcomes of tenofovir disoproxil fumarate (TDF) treatment in Asian-American adults with chronic hepatitis B in real-life practice in the US: a prospective open label study. Hepatology 2013; 58 (S1): 696A